Long-Term Adjuvant Interferon Treatment of Human Osteosarcoma: A pilot study

References

• Strander H. Interferon treatment of human neoplasia. Adv Cancer Res 1986; 46: 1–265
   PubMed Web of Science ®Google Scholar
• Strander H, Cantell K, Carlström G, Jakobsson P. Systemic administration of potent interferon to man. J Natl Cancer Inst 1973; 51: 733–42
   PubMed Web of Science ®Google Scholar
• Cantell K, Hirvonen S. Large‐scale production of human leukocyte interferon containing 100 MU per ml. J Gen Virol 1978; 39: 541–3
   PubMed Web of Science ®Google Scholar
• Adamson U, Aparisi T, Broström L Å, et al. Interferon treatment of human osteosarcoma. Pontificiae Acad Scient Scripta Varia 1979; 383–406
   Google Scholar
• Strander H, Bauer H C F, Brosjö O, . Osteosarcoma management and interferon. Clinical aspects of interferons, Revel, et al. Kluwer Acad Publ. 1988; 165–81
   Google Scholar
• Strander H, Bauer H C F, Brosjö O, . Adjuvant interferon treatment in human osteosarcoma. Osteosarcoma in adolescents and young adults: New developments and controversies, Koops Humphrey, Postma Molenaar, et al. Kluwer Acad Publ, Boston 1993; 29–32
   Google Scholar
• Crane J L, Jr, Glasgow L A, Kern E R, Youngner J. Inhibition of murine osteogenic sarcomas by treatment with type I and type II interferon. J Natl Cancer Inst 1978; 61: 871–4
   PubMedGoogle Scholar
• Hofmann V, Grosurth P, Morant R, Cserbati M, Honegger H P, Hochstetter A. Effects of leukocyte interferon (E. coli) on human bone sarcoma in vitro and in the nude mouse. Eur J Cancer Clin Oncol 1985; 21: 859–63
   PubMedGoogle Scholar
• Strander H, Einhorn S. Effet of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int J Cancer 1987; 19: 468–73
   Google Scholar
• Harju V T, Alitalo R, Andersson L C. Divergent in vitro effects of recombinant interferons on human osteosarcoma cells. Bone 1990; 11: 247–51
   PubMedGoogle Scholar
• Masuda S, Fukuma H, Beppu Y. Antitumor effect of human leukocyte interferon on human osteosarcoma trans‐planted into nude mice. Eur J Cancer Clin Oncol 1983; 19: 1521–8
   PubMedGoogle Scholar
• Gomi K, Oka T, Moromoto M. Antitumor effect of human recombinant interferon‐gamma and ‐beta against human osteosarcoma transplanted into nude mice. J. PharmacoBiodyn 1986; 9: 879–88
   PubMedGoogle Scholar
• Brosjö O, Bauer H C F, Broström L ‐Å, Nilsson O S, Reinholt F, Tribukait B. Growth inhibition of human osteosarcomas in nude mice by human interferon‐alpha: Significance of dose and tumor differentiation. Cancer Res 1987; 47: 258–62
   PubMed Web of Science ®Google Scholar
• Bauer H C, Brosjö O, Strander H. Comparison of growth inhibiting effect of natural and recombinant interferon‐alpha on human osteosarcomas in nude mice. J Interferon Res 1987; 7: 365–9
   PubMedGoogle Scholar
• Forster S, Trifitt J T, Bauer H C F, et al. Interferon inhibited human osteosarcoma xenografts induce host bone in nude mice. J Bone Mineral Res 1988; 3: 199–202
   PubMed Web of Science ®Google Scholar
• Brosjö O, Bauer H C F, Nilsson O S, Halvorsen D, Reinholt F P, Tribukait B. Effect of human interferon‐alpha and interferon‐gamma on growth, histology, and DNA content of human osteosarcomas in nude mice. J Interferon Res 1989; 9: 475–89
   PubMedGoogle Scholar
• Broström L ‐Å, Strander H, Nilsonne U. Survival in osteosarcoma in relation to tumor size and location. Clin Orthop 1982; 167: 250–4
   Google Scholar
• Broström L ‐Å, Ingimarsson S, Strander H, Söderberg G. Adjuvant interferon treatment and the late development of cerebral metastases in a patient with osteosarcoma. Acta Orthop Scand 1980; 51: 589–94
   PubMed Web of Science ®Google Scholar
• Ingimarsson S, Cantell K, Strander H. Side effects of long term treatment with human leukocyte interferon. J Infect Dis 1979; 140: 560–3
   PubMedGoogle Scholar
• Broström L ‐Å, Aparisi T, Ingimarsson S, et al. Can historical controls be used in current clinical trials in osteosarcorna? Analysis of prognostic factors. In J Radiat Oncol Biol Phys 1980; 6: 1711–5
   PubMedGoogle Scholar
• Einhorn S, Strander H. Is interferon tissue specific? Effect of human leukocyte and fibroblast interferons on the growth of lymphoblastoid and osteosarcoma cell lines. J Gen Virol 1977; 35: 573–7
   PubMed Web of Science ®Google Scholar
• Diez R A, Perdereau B, Peter M, Dorval T, Gongora R, Falcoff E T. Scintigraphic study of radiolabelled interferonalpha in osteosarcoma patients. Clin Pharmacokinet 1990; 18: 82–9
   PubMedGoogle Scholar
• Gresser I. Antitumor effects of interferon. Acta Oncol 1989; 28: 347–53
   PubMed Web of Science ®Google Scholar
• Ingimarsson S, Bergström K, Broström L Å, Cantell K, Strander H. Effect of longterm treatment with human leukocyte interferon on various laboratory parameters. Acta Mec Scand 1980; 208: 155–9
   PubMedGoogle Scholar
• Ingimarsson S, Cantell K, Strander H. Acute infections patients receiving interferon. Inter feron‐properties and clinical uses, Hill Dorn Khan. Wadley Institutes, Dallas 1980; 633
   Google Scholar